Unmasking the STI Crisis: At-Home Testing’s Role in Overcoming STI Testing
With at-home STI testing kits, people can get tested in the comfort and privacy of their own homes. These test kits are available at most pharmacies and are easy to use.
With at-home STI testing kits, people can get tested in the comfort and privacy of their own homes. These test kits are available at most pharmacies and are easy to use.
Jona, a New York-based gut microbiome testing startup, emerged from stealth with $5 million in funding. The company's at-home microbiome profiling kit educates users about how the community of microorganisms residing in their gut impacts their overall health. The platform also offers recommendations concerning diet and lifestyle modifications based on users’ personal health goals.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Thanks to continued advances in technology and laboratory information systems (LIS) that fully support a lab’s operational and financial operations, and a growing trend of consumerism in healthcare, clinical labs now have the opportunity to increase revenue and expand into other areas of the care continuum.
Through the partnership, members of Caraway can order an STI Kit, which is delivered to their door and is geared toward Gen Z. The kits have tests for STIs and sexual health, including chlamydia, gonorrhea, syphilis, HIV, hepatitis C, trichomoniasis, candidiasis and bacterial vaginosis. Members then ship the tests to be evaluated at one of Ash’s lab partners, and Caraway then reaches out to the patient with results. If treatment is needed, the patients are connected with a provider on Caraway’s team.
After launching an at-home vaginal microbiome test in 2021, Evvy its expanding its services. After taking a test, consumers can received personalized treatment, which may include prescriptions and one-on-one health coaching.
Poplin sells tests for couples looking to know more about their health before they start trying to get pregnant. After traditionally offering their tests in labs, Poplin is partnering with Getlabs to reach consumers in their homes.
The funding was led by Bold Capital Group. Other investors of the company include Khosla Ventures, WestRiver Group and Glico. In total, Viome has raised more than $150 million.
Morgan Health made the investment in an effort to meet the rising demand for at-home care. The funding will help LetsGetChecked further expand its platform and reach more people.
Panelists at a session on diagnostics at MedtechVision 2022, a hybrid conference organized by MedtechWomen stressed that consumer and physician experience with a product is what is key in medtech innovation compared with simply adding bells and whistles.
Young people ages 15 to 24 account for half of all new sexually transmitted infections, but widespread testing may be hindered by confidentiality concerns. At-home, mail-in testing offers a convenient, safe and private option to screen for STIs.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Menlo Park-based company is building a service for quick at-home health services, such as lab draws and Covid-19 testing. The company is looking to build the “DoorDash for lab draws,” raising $33 million from backers.
The Food and Drug Administration granted an emergency use authorization for an at-home Covid-19 and flu test kit by Labcorp. It uses a test that was developed by Roche and authorized last year.
The diagnostics company currently has an authorized at-home Covid-19 test, and plans to expand into flu tests and other diagnostics. After pricing its stock at $16 per share, it climbed to $20 on Friday.
The call to action is that point-of-care testing needs to move to the home and it needs to be supported by a Medicaid or Medicare billing code to support insurance coverage and payment for the testing.
The at-home testing startup plans to launch a broader virtual care offering after raising $150 million in funding. It plans to roll out virtual visits and offer prescription medications, in addition to building out its array of tests.